The Vector core facility produces viral tools for gene transfer highly concentrated under different scales. iVector is specialized in lentiviral systems as it benefits in house from the experience of the biotechnology and biotherapy Institut du Cerveau – ICM/CNRS team. Since the use of adenoviruses and AAV systems in the field of research in neurobiology is constantly increasing, iVector has developed production of AAV serotypes 2, retro2 & 9 as well as canine adenovirus CAV-2 in addition to its lentiviral system. iVector is making these tools available for any academic and industrial partner. iVector implements continuously in his services portfolio gene transfer innovative technologies (ie: CRISPRs, Split-reporters, DNA/RNA based libraries, …) to allow new approaches in basic research and lead to new applications in genetic engineering, curative and regenerative medicine (gene and cell therapy, tissue engineering and vaccines). iVector premises for production and manipulation of viral particles were designed to match both Biosafety Level 2 (BSL2) and Biosafety Level 3 (BSL3) in accordance to national and European regulations. We have access to, we develop, a large and various collection of viral vectors that allows us to provide quickly a tailored solution that fits researchers’ needs for their in vitro and in vivo applications. iVector is part of the Institut du Cerveau – ICM core facility network (genotyping, histology, microscopy, cellular culture…) which facilitates translational research projects.
• Custom services: Lentiviral systems, AAV and CAV2 viral vectors design, construction and viral particles production for research open to academic and industrial partners.
• Our viral vectors tools are intensively used for: Cell and tissue transductions (Brain, CNS,…); In vivo viral transgenesis (mouse, rat, animal models); Primary cells immortalization; Stem cells, iPS transduction; Knock-in, knock-out, cell labeling, gene silencing, CRISPR; Constitutive and inducible expression, cell or tissue specific expression; gene and cell therapy, cell engineering, vaccines.
• Scientific & technical consulting for viral vectors design and production.
• Performing yourself your own experimentations in our BSL2 or BSL3 facility is possible after having discussed the technical issues with the lab manager.
Philippe Ravassard —Scientific manager
Blandine Bonnamy —Operational manager
Sofian Laoues—Viral bioproduction
Ghislain Heslaut —Viral bioproduction
CONTRACT RESEARCH SERVICES DELIVERED BY THE VECTOROLOGY PLATFORM AND GENOTYPING-SEQUENCING PLATFORM.